Testing empagliflozin for artery stiffness in veterans with obesity
Compares empagliflozin with a placebo over 12 weeks in veterans with obesity.
Plain-language title generated from the registry record
Registry title: Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
Key facts
- Where
- Columbia, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 60 years old?
Source: NCT06745063, who can take part
Where in United States
- Harry S. Truman Memorial, Columbia, MOColumbia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- VA Office of Research and Development
- Trial code
- NCT06745063
- Record updated
- 22 October 2026
- Original description
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.Read full original descriptionShow less
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
Inclusion: Body mass index (BMI) 30-45 kilograms per square meter (kg/m2); 30-60 years of age at randomization; Evidence of arterial stiffening (defined as Carotid femoral PWV>age-predicted) at screening visit (PMID: 20530030), or presence of Stage I hypertension or higher (PMID: 30354655), or current use of antihypertensive agents.
Exclusion: Use of GLP-1 analogs or SGLT2 inhibitors; Use of hormone replacement therapy; Use of pharmacological therapy for weight loss; Change in anti-hypertensive medication regimen (if in use) during the last 90 days; Diabetes mellitus; Uncontrolled hypertension (>180/90 millimeters of mercury) or systolic <100 millimeters of mercury at screening visit; Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke; Diagnosis of chronic kidney disease; Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin); History of hypersensitivity to nitrates; History of ketoacidosis; History of recurrent UTIs or mycotic genital infections; Unable to provide consent; Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women); Body weight changes >10% within the past 6 months; Use of anticoagulants; Pregnancy.